Teresa Head-Gordon, Chancellor's Professor of Chemistry, Bioengineering, and Chemical and Biomolecular Engineering, joins three colleagues from Berkeley Engineering who have received funding from the C3.ai Digital Transformation Institute for COVID-19 projects.
Scientists from the Innovative Genomics Institute (IGI), the same UC Berkeley group that rapidly popped up a state-of-the-art COVID-19 testing laboratory in March, are now trialing a quicker way to obtain patient samples: through saliva. Saliva, collected in the same way companies like 23andMe and Ancestry.com get samples for DNA genealogy analysis, can be gathered without medical supervision, and that saves time, money and precious PPE.
The innovative Genomics Institute (IGI) has awarded a new research project in the College of Chemistry that is looking at the effects of COVID-19 on STEM mentoring. Headed by Laleh Coté, and including fellow PIs Anne M. Baranger, and Colette Flood, the funding is part of a new IGI Rapid Research Response grant.
A new program called BeArS@home will customize interactive lab experiments that have historically been available only in the classroom for online learning by College of Chemistry undergraduate students this fall. When the COVID-19 pandemic kept students away from campus this spring, Berkeley’s Department of Chemistry had to scramble to keep the laboratory sections working. Now they are getting serious and building the real thing.
The Molecular Sciences Software Institute has launched an open-source website that will allow biomolecular scientists from around the world to share computer-aided drug-testing simulations targeting the protein at the center of COVID-19. Under the leadership of Teresa Head-Gordon, the MolSSI team started work on the COVID-19 website about a month ago, after scores of scientists began discussing ways to share simulation modeling data they had on the coronavirus.
As the number of COVID-19 cases continue to escalate in the United States, healthcare providers across the country are dealing with a shortage of personal protective equipment, which has left many workers on the frontlines vulnerable to catching and transmitting the virus. In the Bay Area, an initiative called Shield the Bay is aiming to address this PPE crunch.
Thanks to Fast Grants, a rapid funding program activated six weeks ago, a group of seven COVID-19 research projects has started at UC Berkeley that could turn up new diagnostic and potential treatments for the infection within months. One project is being lead by Daniel Nomura, a professor of chemistry, molecular and cell biology, and nutritional sciences and toxicology. He is working with a group of investigators, and fellow professors, planning to use innovative chemical biology approaches to develop novel therapeutics against COVID-19.
by Martin Mulvihill (Ph.D. '09, Chem) | Safer Made
With cleaning and sanitizing products flying off the shelves and handwashing jingles becoming ubiquitous, we'd like to consider the chemistry of micro-organism control. There are many ways to effectively remove pathogens, including coronavirus, from surfaces. Most of these products use one of three basic mechanisms to chemically control bacteria and viruses.
BERKELEY, Calif. (KGO) -- A single image helped alert the world to a once-in-a-lifetime side effect of the COVID-19 crisis. It was a satellite map, showing a dramatic drop in pollution levels over China after the country began to effectively quarantine its population. Shortly afterward Ron Cohen, Professor of Chemistry and of Earth and Planetary Sciences at UC Berkeley, predicted a similar effect here in the Bay Area.
UC Berkeley and UCSF Professor Kevan Shokat, along with members of his lab, have joined with other scientists around the world in a unique research project under the auspices of the Quantitative Biosciences Institute Coronavirus Research Group (QBI) spearheaded by UCSF Professor Nevan Krogan. The international team is testing an unusual new approach to identify potential antiviral drugs with proven efficacy to treat SARS-Cov-2 infections. Given the world crisis, the strategy of testing known/approved drugs could help reduce the numbers of deaths in the near term while the world health community battles the epidemic.
